上海多米瑞生物技术

Shanghai Domirui Biotechnology is a biopharmaceutical company dedicated to the discovery and development of innovative targeted protein degradation (TPD) therapies. The company utilizes its proprietary D-Glue and D-PROTAC platforms to create small molecule degraders that target disease-causing proteins, including those previously considered undruggable. Domirui's research focus is primarily on oncology and immunology, aiming to address unmet medical needs and overcome drug resistance in cancer treatment. Its lead pipeline candidates include degraders for Bruton tyrosine kinase (BTK) and the androgen receptor (AR). By leveraging the body's natural protein disposal system, the company seeks to provide more effective and durable treatment options for patients.